Welcome to our dedicated page for BIO-PATH HOLDINGS news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on BIO-PATH HOLDINGS stock.
Bio-Path Holdings develops targeted nucleic acid drug candidates using its DNAbilize® liposomal delivery and antisense RNAi nanoparticle technology. Its disclosed pipeline includes prexigebersen (BP1001), which targets Grb2 for blood cancers; BP1001-A, a modified prexigebersen candidate studied in solid tumors and metabolic disease models; BP1002, which targets Bcl-2 for blood cancers and solid tumors; and a STAT3 antisense program.
Company news commonly covers clinical and preclinical program updates, obesity and Type 2 diabetes research, acute myeloid leukemia and other oncology studies, patent grants tied to DNAbilize®, financial results, investor presentations, and corporate or operational updates affecting the biotechnology portfolio.
Bio-Path Holdings (Nasdaq: BPTH) has announced its intention to offer and sell shares of its common stock in a public offering, subject to market conditions. Roth Capital Partners is the sole placement agent for this offering. The net proceeds will be utilized for working capital and corporate purposes. A preliminary prospectus will be filed with the SEC as part of an effective shelf registration statement declared on June 5, 2019. This offering may present investors with new opportunities, although specific terms and timing remain uncertain.
Bio-Path Holdings (NASDAQ:BPTH) announced the granting of U.S. Patent No. 10,898,506, enhancing protection for its DNAbilize technology. This patent covers P-ethoxy nucleic acids for liposomal formulation, strengthening the company's intellectual property. Additionally, a notification for U.S. Patent No. 10,927,379 related to its lead product prexigebersen is set to issue on February 23, 2021. The new patents bolster Bio-Path's competitive edge and safeguard ongoing clinical trials, particularly in treating acute myeloid leukemia.
Bio-Path Holdings (NASDAQ:BPTH) has initiated a Phase 1 clinical trial for BP1002, targeting Bcl-2 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL).
The trial aims to enroll six patients, assessing safety, tolerability, and pharmacokinetics over a four-week treatment period. BP1002 has demonstrated potent inhibition of Bcl-2 in preclinical studies, potentially offering a new therapy for patients resistant to existing treatments like venetoclax. With notable unmet medical needs in this area, Bio-Path anticipates preliminary efficacy results.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its Q3 2020 financial results, reporting a net loss of $3.0 million ($0.80 per share), an increase from $2.2 million ($0.78 per share) in Q3 2019. R&D expenses rose to $2.0 million due to Phase 2 trial enrollment for prexigebersen in AML. The company has $12.1 million in cash remaining and raised approximately $4.6 million through a stock offering post-Q3. Significant advancements include the initiation of the first patient in Stage 2 of the Phase 2 trial for AML and a strategic patent allowance for prexigebersen.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a conference call and audio webcast on November 13, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020. The company specializes in developing cancer treatments using its DNAbilize® antisense RNAi nanoparticle technology. Its lead candidate, prexigebersen (BP1001), is advancing in a Phase 2 study for blood cancers, while prexigebersen-A is being considered for Phase 1 trials in solid tumors. Details for accessing the call are provided in the announcement.
Bio-Path Holdings (NASDAQ: BPTH) announced a notice of allowance from the United States Patent and Trademark Office for claims related to its lead product candidate, prexigebersen, in combination with certain cancer therapies. This patent enhances the company's intellectual property portfolio, providing broad protection for prexigebersen against various cancers. Currently, prexigebersen is undergoing a Phase 2 clinical trial for acute myeloid leukemia. The new patent supports ongoing investments in this treatment option for patients with limited alternatives.
Bio-Path Holdings, a biotechnology firm, is set to present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:30 a.m. ET. CEO Peter H. Nielsen will lead the presentation. The company specializes in developing targeted nucleic acid cancer drugs utilizing its proprietary DNAbilize™ technology. Its lead candidate, prexigebersen (BP1001), is in a Phase 2 study for blood cancers and is also under FDA consideration for solid tumors. Follow-up candidate BP1002 targets lymphoma and solid tumors.
Bio-Path Holdings (NASDAQ: BPTH) reported a net loss of $2.0 million for Q2 2020, an improvement from a $2.5 million loss in Q2 2019. R&D expenses decreased to $1.0 million from $1.5 million, while G&A expenses remained stable at $1.0 million. As of June 30, 2020, cash stood at $14.4 million, down from $20.4 million at year-end 2019. The company has initiated the first patient dosing in Stage 2 of its Phase 2 trial for prexigebersen in treating acute myeloid leukemia and plans to start a Phase 1 study for solid tumors by year-end.
Bio-Path Holdings (BPTH) reported Q1 2020 financial results, showing a net loss of $3.3 million, or $0.90 per share, compared to a loss of $1.5 million in Q1 2019. R&D expenses surged to $2.0 million due to clinical trial preparations. The company plans to initiate a Phase 2 safety trial for its lead candidate, prexigebersen, in AML. COVID-19 has limited site access but has not significantly impacted operations. Cash reserves stood at $17.9 million as of March 31, 2020.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a live conference call on May 15, 2020, at 8:30 a.m. ET, to discuss its financial results for Q1 ending March 31, 2020, and provide a business overview. The call can be accessed domestically at (844) 815-4963 or internationally at (210) 229-8838, using conference ID 7973458. The company's lead product, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers, with plans for Phase 1 studies in solid tumors pending FDA consideration.